Researchers said the results suggest UnitedHealth may be sidestepping government rules meant to keep a lid on exorbitant ...

Leaders are worried some of the sector’s persistent challenges — like finance pressures and worker burnout — could worsen ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for ...

Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of Summa.

The $600 million deal was foreshadowed during the company’s third quarter earnings call this month, when CEO Kevin Hammons ...

The goodwill impairment charge is meant to realign Centene’s value on its own books with its value in the market, which has ...

Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.

Lawmakers called for more transparency about how hospitals are using 340B revenue, including audits of participating ...

Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and ...

Measuring financial returns from AI can be challenging, experts said at the HLTH conference last week. But other metrics, ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...